Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/112859
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

The multifactorial nature of Alzheimer's disease for developing potential therapeutics

AutorCarreiras, M. Carmo; Mendes, Eduardo; Perry, M. Jesús; Francisco, Ana Paula; Marco-Contelles, José CSIC ORCID
Palabras claveoxidative stress
metal chelators
MAO
Dual AChE/BuChE inhibitors
ChEs
Ca2+ dishomeostasis

Alzheimer's disease
Fecha de publicación2013
EditorBentham Science Publishers
CitaciónCurrent Topics in Medicinal Chemistry 13: 1745-1770 (2013)
ResumenAlzheimer's disease (AD) is a multifactorial neurodegenerative disorder with several target proteins contributing to its aetiology. Pathological, genetic, biochemical, and modeling studies all point to a critical role of Aβ aggregation in AD. Though there are still many enigmatic aspects of the Aβ cascade, none of the gaps invalidate the hypothesis. The amyloid hypothesis determines that the production, aggregation and accumulation of Aβ in the brain gives rise to a cascade of neurotoxic events that proceed to neuronal degeneration. Different targets of the disease include APP pathogenic cleavage, cytoskeletal destabilization, neurotransmitter and ion dyshomeostasis, metal ion accumulation, protein misfolding, oxidative stress, neuronal death and gene mutations. Thus, disease-modifying treatments for AD must interfere with the pathogenic steps responsible for the clinical symptoms: the deposition of extracellular Aβ plaques, the intracellular neurofibrillary tangles, inflammation, oxidative stress, iron deregulation, among others. The observations supporting the development of multifunctional compounds in association with the perception that several dual binding site AChEIs were able to reach different targets guided the development of a new drug design strategy, the multi-target-directed-ligand (MTDL) approach. This may be regarded as the buildup of hybrid molecules composed of distinct pharmacophores of different drugs. Thus, each pharmacophore of the new hybrid drug would preserve the capacity of interacting with their specific sites on the targets and, therefore, generate multiple specific pharmacological responses which would enable the treatment of multi-factorial diseases. This review summarizes a few current therapeutic trends on MTDL strategy intended to halt or revert the progression of the disease. © 2013 Bentham Science Publishers.
URIhttp://hdl.handle.net/10261/112859
DOI10.2174/15680266113139990135
Identificadoresdoi: 10.2174/15680266113139990135
issn: 1568-0266
e-issn: 1873-4294
Aparece en las colecciones: (IQOG) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

SCOPUSTM   
Citations

184
checked on 20-mar-2024

WEB OF SCIENCETM
Citations

181
checked on 27-feb-2024

Page view(s)

320
checked on 28-mar-2024

Download(s)

108
checked on 28-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.